Immunosuppressant Peptide Abu-TGIRIS-Abu-NH2 and its Application for Treatment of Multiple Sclerosis

Abstract

Immunosuppressant peptide immunocortin for the first time was described in 1993. It corresponds to residues 11–20 of human Ig heavy chain (conserved motif of VH domain). There are no data about production of immunocortin by proteolysis of Ig in vivo. Synthetic immunocortin in concentration ~ 10−9 M suppresses phagocytosis in peritoneal macrophages, ConA-dependent blast transformation of rat lymphocytes, exhibits ACTH-like neurotropic activity and was suggested as a potential drug for treatment of a multiple sclerosis (MS). Here, we report a sequence and method of synthesis of Abu-TGIRIS-Abu-NH2 (Abu, alpha-aminobutyric acid), an artificial analogue of immunocortin. Biological trials of peritoneally injected Abu-TGIRIS-Abu-NH2 gave an evidence of its better efficacy versus immunocortin in a test for suppression of the experimental autoimmune encephalomyelitis (EAE) in Dark Agouti (DA) rats.

Targeted Delivery Platforms for the Treatment of Multiple Sclerosis

“…Immunocortin was modified to obtain Abu-TGIRIS-Abu-NH2 (synthetic artificial anti-MS peptide). The prepared peptide reduced EAE symptoms in the animal model …”

“…The prepared peptide reduced EAE symptoms in the animal model. 221 Removal of self-reactive lymphocytes by the thymus is accomplished through a mechanism called "central tolerance", which indicates that the immune system does not attack selfpeptides. Accordingly, appropriate concentrations of altered peptide ligands (APLs), antigenic protein/peptide, and dualfunction peptides can be used to reduce the immunogenicity of some specific antigen/allergens involved in the EAE model through an antigen-specific immunotherapy (SIT) approach.…”